Initial Pseudomonas aeruginosa infection in patients with cystic fibrosis: characteristics of eradicated and persistent isolates G.A. Tramper-Stranders,

Slides:

Advertisements

Similar presentations

Models for the organisation of hospital infection control and prevention programmes B. Gordts Clinical Microbiology and Infection Volume 11, Pages

Advertisements

C.-S. Lee, J.-H. Lee Clinical Microbiology and Infection

Development of resistance in Pseudomonas aeruginosa obtained from patients with cystic fibrosis at different times F.B. Spencker, L. Staber, T. Lietz,

Rapid single-nucleotide polymorphism-based identification of clonal Pseudomonas aeruginosa isolates from patients with cystic fibrosis by the use of real-time.

Typing of Pseudomonas aeruginosa strains from patients with cystic fibrosis: phenotyping versus genotyping Nicole Renders, Alex van Belkum, Alfonso Barth,

Antimicrobial therapy for pulmonary pathogenic colonisation and infection by Pseudomonas aeruginosa in cystic fibrosis patients R. Cantón, N. Cobos,

Gut bacterial microbiota and obesity

Approach to diagnosis of infective endocarditis

A. M. M. de Vrankrijker, C. K. van der Ent, F. T. van Berkhout, R. K

Association of vancomycin serum concentrations with efficacy in patients with MRSA infections: a systematic review and meta-analysis T. Steinmetz, N.

Clinical characteristics of Haemophilus influenzae meningitis in Denmark in the post- vaccination era T.I. Pedersen, M. Howitz, C. Østergaard Clinical.

Type 3 secretion system effector genotype and secretion phenotype of longitudinally collected Pseudomonas aeruginosa isolates from young children diagnosed.

C.-S. Lee, J.-H. Lee Clinical Microbiology and Infection

J.-P. Van geertruyden Clinical Microbiology and Infection

Virological tools to diagnose and monitor hepatitis C virus infection

Pseudomonas aeruginosa diversity in distinct paediatric patient groups

R. Cantón Clinical Microbiology and Infection

Semi-national surveillance of fungaemia in Denmark 2004–2006: increasing incidence of fungaemia and numbers of isolates with reduced azole susceptibility

Meropenem in cystic fibrosis patients infected with resistant Pseudomonas aeruginosa or Burkholderia cepacia and with hypersensitivity to β-lactam antibiotics

Should standardized susceptibility testing for microbial biofilms be introduced in clinical practice? T. Coenye, D. Goeres, F. Van Bambeke, T. Bjarnsholt

Rapid single-nucleotide polymorphism-based identification of clonal Pseudomonas aeruginosa isolates from patients with cystic fibrosis by the use of real-time.

Pan-drug-resistant Pseudomonas aeruginosa causing nosocomial infection at a university hospital in Taiwan P.R. Hsueh, S.P. Tseng, L.J. Teng, S.W. Ho

Clinical Microbiology and Infection

Holt Hanne M. , Søgaard Per , Gahrn-Hansen Bente

Assessment of nephrotoxicity in patients receiving amphotericin B lipid complex: a pharmacosurveillance study in Spain J.-M. Aguado, C. Lumbreras, D.

Vector control: a cornerstone in the malaria elimination campaign

Switch to oral antibiotics in the treatment of infective endocarditis is not associated with increased risk of mortality in non–severely ill patients

Sofie Arens, Jan Verhaegen, Ludo Verbist

A. Oliver, A. Mena Clinical Microbiology and Infection

Training for the infectious diseases speciality in Norway

Long-term azitromycin treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection; an observational cohort study Christine Rønne.

Improved isolation of Stenotrophomonas maltophilia from the sputa of patients with cystic fibrosis using a selective medium M. Denton, M.J. Hall, N.J.

Gerd Döring, Patrick Flume, Harry Heijerman, J. Stuart Elborn

Implementation of European standards of care for cystic fibrosis �� Control and treatment of infection J.S. Elborn, M. Hodson, C. Bertram Journal of.

Elements of design: the knowledge on which we build

Clinical Microbiology and Infection

W. van den Bijllaardt, I.T. Overdevest, A.G. Buiting, J.J. Verweij

Transmission of respiratory syncytial virus at the paediatric intensive-care unit: a prospective study using real-time PCR A.C. van de Pol, J.W.A. Rossen,

In vitro selection of antibiotic resistance in Pseudomonas aeruginosa

Levofloxacin in the treatment of ventilator-associated pneumonia

Metagenomics and probiotics

M. C. Alanin, K. G. Nielsen, C. von Buchwald, M. Skov, K. Aanaes, N

Effectiveness of inhaled tobramycin in eradicating Pseudomonas aeruginosa in children with cystic fibrosis Sanja Stanojevic, Valerie Waters, Joseph L.

T.M. File Clinical Microbiology and Infection

Molecular epidemiology of Pseudomonas aeruginosa in intensive care units over a 10- year period ( ) M. Cuttelod, L. Senn, V. Terletskiy, I. Nahimana,

Systematic review of antibiotic consumption in acute care hospitals

Update on antifungal resistance in Aspergillus and Candida

Harmonised monitoring of antimicrobial resistance in Salmonella and Campylobacter isolates from food animals in the European Union S. Bronzwaer Clinical.

Abstracts cont. Clinical Microbiology and Infection

Evolution of Pseudomonas aeruginosa virulence in infected patients revealed in a Dictyostelium discoideum host model E. Lelong, A. Marchetti, M. Simon,

Effect of metronidazole versus standard care on length of stay of patients admitted with severe infectious mononucleosis: a randomized controlled trial

Molecular epidemiology and virulence factors of pyogenic liver abscess causing Klebsiella pneumoniae in China Y. Luo, Y. Wang, L. Ye, J. Yang Clinical.

Current experience in treating invasive zygomycosis with posaconazole

H. Leblebicioglu, C. Eroglu Clinical Microbiology and Infection

Sequential time to positivity of blood cultures can be a predictor of prognosis of patients with persistent Staphylococcus aureus bacteraemia M.-S. Hsu,

Statin use and clinical outcomes among pneumonia patients

Changing pattern of candidaemia 2001–2006 and use of antifungal therapy at the University Hospital of Vienna, Austria E. Presterl, F. Daxböck, W. Graninger,

Nebulized hypertonic saline treatment in hospitalized children with moderate to severe viral bronchiolitis Z. Luo, Z. Fu, E. Liu, X. Xu, X. Fu, D. Peng,

K. Kaier, N.T. Mutters, U. Frank Clinical Microbiology and Infection

A. van Samkar, M. C. Brouwer, Y. Pannekoek, A. van der Ende, D

J.J. Keller, M.-C. Tsai, C.-C. Lin, Y.-C. Lin, H.-C. Lin

Modelling during an emergency: the 2009 H1N1 influenza pandemic

Susceptibility of multi-drug-resistant Pseudomonas aeruginosa in intensive care units: results from the European MYSTIC study group† H. Goossens Clinical.

J.L. Balcázar Clinical Microbiology and Infection

G.C. Schito Clinical Microbiology and Infection

Impact of antibiotic restrictions: the patient's perspective

B. Martha, D. Croisier, A. Fanton, K. Astruc, L. Piroth, F. Huet, P

CMI readers' survey Clinical Microbiology and Infection

The future of diagnostic bacteriology

Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience C.R.

Presentation transcript:

Initial Pseudomonas aeruginosa infection in patients with cystic fibrosis: characteristics of eradicated and persistent isolates G.A. Tramper-Stranders, C.K. van der Ent, S. Molin, L. Yang, S.K. Hansen, M.H. Rau, O. Ciofu, H.K. Johansen, T.F.W. Wolfs Clinical Microbiology and Infection Volume 18, Issue 6, Pages 567-574 (June 2012) DOI: 10.1111/j.1469-0691.2011.03627.x Copyright © 2012 European Society of Clinical Infectious Diseases Terms and Conditions

FIG. 1 Number of participants and flow diagram. NL, the Netherlands; DK, Denmark. *P. aeruginosa free after first treatment cycle for >1 year. †P. aeruginosa intermittently isolated in the year after initial infection; eradication after >1 treatment cycle or eradication after first treatment cycle and re-isolation in the year after initial infection. #No eradication despite several treatment cycles and subsequent genotypes identical. Clinical Microbiology and Infection 2012 18, 567-574DOI: (10.1111/j.1469-0691.2011.03627.x) Copyright © 2012 European Society of Clinical Infectious Diseases Terms and Conditions

FIG. 2 (a) Virulence factor assay results with medians. (b) Cytotoxicity (% lysis with medians) on IB3-1 cell layer (dotted line represents 5% cut off) (• eradicated isolates and ▴ persistent isolates). Clinical Microbiology and Infection 2012 18, 567-574DOI: (10.1111/j.1469-0691.2011.03627.x) Copyright © 2012 European Society of Clinical Infectious Diseases Terms and Conditions